Long-term credit rating of Promomed DM is confirmed at ruA-, outlook stable

Promomed 28 November 2022

On November 24, 2022, the Expert RA rating agency confirmed the credit rating of the non-financial company Promomed DM LLC at ruА-. The rating outlook is stable.


These results are achieved thanks to the Group's strong financial results since the last update. The agency's experts also assess the resilience to external shocks as above average, the financial policy of Promomed Group as balanced, and the level of debt burden as comfortable.

«The strategy of Promomed Group is aimed at solving two of the most important tasks for today – the development of new highly effective domestic drugs for patients and strengthening the national drug independence. Now the main focus is on expanding the product portfolio and scaling up production, which will help maintain growth rates and ensure drug supply security. For us, the rating procedure confirming creditworthiness is an objective analysis of our team work, and the high assessment of experts is an excellent motivation for further movement forward,» commented Maxim Smagin, CEO of Promomed Group.

The press release of the Expert RA rating agency is published on the website raexpert.ru